ATE132848T1 - Verfahren zur herstellung von sertralin- zwischenprodukten - Google Patents

Verfahren zur herstellung von sertralin- zwischenprodukten

Info

Publication number: ATE132848T1
Authority: AT; Austria
Prior art keywords: pct; intermediate products; sertraline; date jan; sec
Prior art date: 1991-07-11

Application number

AT92914659T

Other languages

German (de)

English (en)

Inventor

Michael Trevelyan Williams

Willard Mckowan Welch Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-11

Filing date

1992-07-03

Publication date

1996-01-15

1992-07-03 Application filed by Pfizer filed Critical Pfizer

1996-01-15 Application granted granted Critical

1996-01-15 Publication of ATE132848T1 publication Critical patent/ATE132848T1/de

Links

229960002073 sertraline Drugs 0.000 title abstract 2
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 2
239000013067 intermediate product Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/14—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT92914659T 1991-07-11 1992-07-03 Verfahren zur herstellung von sertralin- zwischenprodukten ATE132848T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB919114948A GB9114948D0 (en)	1991-07-11	1991-07-11	Process for preparing sertraline intermediates

Publications (1)

Publication Number	Publication Date
ATE132848T1 true ATE132848T1 (de)	1996-01-15

Family

ID=10698171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92914659T ATE132848T1 (de)	1991-07-11	1992-07-03	Verfahren zur herstellung von sertralin- zwischenprodukten

Country Status (14)

Country	Link
US (1)	US5442116A (2)
EP (1)	EP0595851B1 (2)
JP (1)	JP2563754B2 (2)
AT (1)	ATE132848T1 (2)
CA (1)	CA2109818C (2)
DE (1)	DE69207601T2 (2)
DK (1)	DK0595851T3 (2)
ES (1)	ES2082481T3 (2)
FI (1)	FI112209B (2)
GB (1)	GB9114948D0 (2)
GR (1)	GR3019122T3 (2)
IE (1)	IE71029B1 (2)
PT (1)	PT100673B (2)
WO (1)	WO1993001161A1 (2)

Families Citing this family (929)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG41929A1 (en) *	1992-09-25	1997-08-15	Commw Scient Ind Res Org	Target binding polypeptide
ES2217748T3 (es) *	1998-03-18	2004-11-01	Ciba Specialty Chemicals Holding Inc.	Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
FR2777000B1 (fr) *	1998-04-01	2002-09-27	Catalys	Procede de preparation de la sertraline racemique
SE9801992D0 (sv) *	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
IL132500A0 (en)	1998-10-29	2001-03-19	Pfizer Prod Inc	Stereoselective microbial reduction of a racemic tetralone
WO2000025598A1 (en) *	1998-11-03	2000-05-11	Dandy A/S	Sucrose fatty acid esters for use as increased release of active ingredients
EP2075335A3 (en)	1998-12-22	2009-09-30	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
ATE264831T1 (de)	1999-07-29	2004-05-15	Ciba Sc Holding Ag	Verfahren zur cis-selektiven katalytischen hydrierung von cyclohexylidenaminen
DK174219B1 (da) *	1999-10-27	2002-09-30	Gea Farmaceutisk Fabrik As	Forbedret syntese af racemisk sertralin
US7056702B2 (en)	2002-12-16	2006-06-06	Kimberly Clark Co	Detecting lipocalin
ES2242555T1 (es) *	2003-04-14	2005-11-16	Teva Pharmaceutical Industries Limited	Hidrogenacion de intermediarios de imina de sertralina con catalizadores.
EP1954719A2 (en)	2005-12-02	2008-08-13	Genentech Inc.	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
ES2567402T3 (es)	2006-05-30	2016-04-22	Genentech, Inc.	Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
US7893053B2 (en) *	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
US20100008910A1 (en)	2006-09-12	2010-01-14	John Chant	Methods and compositions for the diagnosis and treatment of cancer
KR20140116546A (ko)	2006-10-27	2014-10-02	제넨테크, 인크.	항체 및 면역접합체 및 이들의 용도
AR065271A1 (es)	2007-02-09	2009-05-27	Genentech Inc	Anticuerpos anti-robo4 y sus usos
MX2009008981A (es)	2007-03-02	2009-09-02	Genentech Inc	Prediccion de respuesta a un inhibidor her.
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
BRPI0811930B8 (pt)	2007-05-21	2021-05-25	Genentech Inc	métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo
KR20190140090A (ko)	2007-07-09	2019-12-18	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
AU2008304748C1 (en)	2007-09-26	2014-06-12	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
WO2009062102A2 (en)	2007-11-07	2009-05-14	Genentech, Inc.	Compositions and methods for treatment of microbial disorders
TWI580694B (zh)	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
EP3524620A1 (en)	2008-10-14	2019-08-14	Genentech, Inc.	Immunoglobulin variants and uses thereof
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
CA2746330C (en)	2008-12-23	2017-08-29	Genentech, Inc.	Immunoglobulin variants with altered binding to protein a
WO2010078376A2 (en)	2008-12-30	2010-07-08	Ventana Medical Systems, Inc.	Fc-specific polymer-conjugated antibodies and their diagnostic use
JP5616428B2 (ja)	2009-04-07	2014-10-29	ロシュグリクアートアクチェンゲゼルシャフト	三価の二重特異性抗体
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2011014457A1 (en)	2009-07-27	2011-02-03	Genentech, Inc.	Combination treatments
US20110039300A1 (en)	2009-08-10	2011-02-17	Robert Bayer	Antibodies with enhanced adcc functions
CN104059955A (zh)	2009-08-11	2014-09-24	弗·哈夫曼-拉罗切有限公司	在无谷氨酰胺的细胞培养基中的蛋白质生产
MX2012001716A (es)	2009-08-14	2012-04-02	Genentech Inc	Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
US20110053223A1 (en)	2009-08-14	2011-03-03	Robert Bayer	Cell culture methods to make antibodies with enhanced adcc function
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
SG179070A1 (en)	2009-09-11	2012-04-27	Genentech Inc	Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
KR20120108967A (ko)	2009-09-16	2012-10-05	제넨테크, 인크.	코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
CA2775880A1 (en)	2009-09-30	2011-04-07	Genentech, Inc.	Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
BR112012007778A2 (pt)	2009-10-07	2020-08-11	Genentech, Inc.	método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico.
WO2011060015A1 (en)	2009-11-11	2011-05-19	Genentech, Inc.	Methods and compositions for detecting target proteins
CN102770529B (zh)	2009-11-17	2018-06-05	Musc研究发展基金会	针对人核仁素的人单克隆抗体
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
JP5818805B2 (ja)	2009-12-11	2015-11-18	ジェネンテック，インコーポレイテッド	抗ｖｅｇｆ−ｃ抗体及びその使用方法
JP6214161B2 (ja)	2009-12-21	2017-10-18	ジェネンテック，インコーポレイテッド	抗体製剤
DK2536748T3 (da)	2010-02-18	2014-10-13	Genentech Inc	Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
AR080795A1 (es)	2010-03-24	2012-05-09	Genentech Inc	Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
CN103068378B (zh)	2010-05-10	2016-07-06	中央研究院	具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
RU2613886C2 (ru)	2010-06-03	2017-03-21	Дженентек, Инк.	Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
BR112012027995A2 (pt)	2010-06-18	2017-01-10	Genentech Inc	anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
WO2012006503A1 (en)	2010-07-09	2012-01-12	Genentech, Inc.	Anti-neuropilin antibodies and methods of use
CA2804246A1 (en)	2010-07-19	2012-01-26	F. Hoffmann-La Roche Ag	Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2848939A1 (en)	2010-07-19	2015-03-18	F. Hoffmann-La Roche AG	Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
JP2013541501A (ja)	2010-08-03	2013-11-14	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
CA2805564A1 (en)	2010-08-05	2012-02-09	Stefan Jenewein	Anti-mhc antibody anti-viral cytokine fusion protein
HUE036077T2 (hu)	2010-08-13	2018-06-28	Roche Glycart Ag	Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
JP5841149B2 (ja)	2010-08-13	2016-01-13	ロシュグリクアートアーゲー	抗テネイシンｃａ２抗体及び使用の方法
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5813114B2 (ja)	2010-08-25	2015-11-17	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｉｌ−１８ｒ１に対する抗体およびその使用
KR20130103734A (ko)	2010-08-31	2013-09-24	제넨테크, 인크.	바이오마커 및 치료 방법
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
MX346500B (es)	2010-11-10	2017-03-22	Genentech Inc *	Metodos y composiciones para inmunoterapia para enfermedad neural.
TWI732259B (zh)	2010-12-16	2021-07-01	美商建南德克公司	關於th2抑制作用之診斷及治療
PE20141114A1 (es)	2010-12-20	2014-09-15	Genentech Inc	Anticuerpos anti-mesotelina e inmunoconjugados
KR20130118925A (ko)	2010-12-22	2013-10-30	제넨테크, 인크.	항-pcsk9 항체 및 사용 방법
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
SG192675A1 (en)	2011-02-09	2013-09-30	Hoffmann La Roche	New iridium-based complexes for ecl
ES2644816T3 (es)	2011-02-09	2017-11-30	Hoffmann-La Roche Ag	Nuevos complejos basados en iridio para ECL
HUE029139T2 (hu)	2011-02-10	2017-02-28	Roche Glycart Ag	Mutáns interleukin-2 polipeptidek
MX2013009151A (es)	2011-02-10	2013-08-29	Roche Glycart Ag	Inmunoterapia mejorada.
JP5768147B2 (ja)	2011-02-28	2015-08-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	一価抗原結合タンパク質
WO2012116926A1 (en)	2011-02-28	2012-09-07	F. Hoffmann-La Roche Ag	Antigen binding proteins
RS56793B1 (sr)	2011-03-02	2018-04-30	Roche Glycart Ag	Cea antitela
HUE065915T2 (hu)	2011-03-11	2024-06-28	Beth Israel Deaconess Medical Ct Inc	Anti-CD40 antitestek és alkalmazásaik
WO2012123297A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Nnmt as marker for chronic obstructive pulmonary disease (copd)
WO2012123294A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Apex1 as marker for chronic obstructive pulmonary disease (copd)
WO2012123296A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Armet as marker for chronic obstructive pulmonary disease (copd)
WO2012123299A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Asc as marker for chronic obstructive pulmonary disease (copd)
ES2583688T3 (es)	2011-03-11	2016-09-21	F. Hoffmann-La Roche Ag	FEN1 como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
WO2012123293A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Seprase as marker for chronic obstructive pulmonary disease (copd)
EP2689252A1 (en)	2011-03-25	2014-01-29	Roche Diagnostics GmbH	MEASUREMENT OF C-TERMINAL proSP-B
SG10201602394QA (en)	2011-03-29	2016-05-30	Roche Glycart Ag	Antibody FC Variants
CA2828890A1 (en)	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
US20120282176A1 (en)	2011-04-20	2012-11-08	Roche Glycart Ag	Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR101992502B1 (ko)	2011-05-12	2019-06-24	제넨테크, 인크.	프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
SI2710035T1 (sl)	2011-05-16	2017-07-31	F. Hoffmann-La Roche Ag	Agonisti FGFR1 in tehnike njihove uporabe
CA2837914A1 (en)	2011-06-15	2012-12-20	F. Hoffmann-La Roche Ag	Anti-human epo receptor antibodies and methods of use
RU2013155695A (ru)	2011-06-30	2015-08-10	Дженентек, Инк.	Препараты антител против с-мет
US20140363438A1 (en)	2011-08-17	2014-12-11	Genentech, Inc.	Neuregulin antibodies and uses thereof
MX349095B (es)	2011-08-23	2017-07-11	Roche Glycart Ag	Moleculas biespecificas de union a antigeno.
RU2014109038A (ru)	2011-08-23	2015-09-27	Рош Гликарт Аг	Антитела к хондроитинсульфат протеогликану меланомы
WO2013026837A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
MY169358A (en)	2011-08-23	2019-03-26	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
JP2014533927A (ja)	2011-09-15	2014-12-18	ジェネンテック，インコーポレイテッド	分化を促進する方法
AU2012312515A1 (en)	2011-09-19	2014-03-13	Genentech, Inc.	Combination treatments comprising c-met antagonists and B-raf antagonists
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
CN103917556B (zh)	2011-10-14	2018-02-06	霍夫曼-拉罗奇有限公司	抗HtrA1抗体及使用方法
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
BR112014010009A2 (pt)	2011-10-26	2017-04-25	Univ California	"anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
PE20142312A1 (es)	2011-10-28	2015-01-25	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma
EP2782932A1 (en)	2011-11-21	2014-10-01	F.Hoffmann-La Roche Ag	Purification of anti-c-met antibodies
BR112014012882A2 (pt)	2011-11-29	2017-06-13	Genentech Inc	método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
WO2013083497A1 (en)	2011-12-06	2013-06-13	F. Hoffmann-La Roche Ag	Antibody formulation
EP2794878B1 (en)	2011-12-22	2020-03-18	F.Hoffmann-La Roche Ag	Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN107119073A (zh)	2011-12-22	2017-09-01	弗·哈夫曼-拉罗切有限公司	表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
AR089434A1 (es)	2011-12-23	2014-08-20	Genentech Inc	Procedimiento para preparar formulaciones con alta concentracion de proteinas
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en)	2012-01-09	2020-06-10	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
KR20140114415A (ko)	2012-01-13	2014-09-26	제넨테크, 인크.	Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
US20130183294A1 (en)	2012-01-18	2013-07-18	Genentech, Inc.	Methods of using fgf19 modulators
EP2804629A1 (en)	2012-01-18	2014-11-26	Genentech, Inc.	Anti-lrp5 antibodies and methods of use
WO2013113641A1 (en)	2012-01-31	2013-08-08	Roche Glycart Ag	Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
WO2013119966A2 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
KR102148303B1 (ko)	2012-02-11	2020-08-26	제넨테크, 인크.	R-스폰딘 전위 및 그의 사용 방법
CA2860600C (en)	2012-02-15	2022-07-26	F. Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
BR112014018374A8 (pt)	2012-03-02	2017-07-11	Roche Glycart Ag	Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
RU2014136886A (ru)	2012-03-27	2016-05-20	Дженентек, Инк.	Диагностика и виды лечения, связанные с ингибиторами her3
SG11201406184XA (en)	2012-03-30	2014-10-30	Genentech Inc	Diagnostic methods and compositions for treatment of cancer
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013256596A1 (en)	2012-05-01	2014-10-09	Genentech, Inc.	Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
EP3605090A1 (en)	2012-05-23	2020-02-05	F. Hoffmann-La Roche AG	Selection method for therapeutic agents
EP2861624A1 (en)	2012-06-15	2015-04-22	F. Hoffmann-La Roche AG	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
WO2014001325A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2871386A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
MX354862B (es)	2012-06-27	2018-03-23	Hoffmann La Roche	Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
JP6247287B2 (ja)	2012-07-04	2017-12-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ビオチン抗体および使用方法
EP3138578B1 (en)	2012-07-04	2022-01-12	F. Hoffmann-La Roche AG	Anti-theophylline antibodies and methods of use
ES2604012T3 (es)	2012-07-04	2017-03-02	F. Hoffmann-La Roche Ag	Conjugados de antígeno-anticuerpo unidos covalentemente
EP3578660A1 (en)	2012-07-05	2019-12-11	F. Hoffmann-La Roche AG	Expression and secretion system
IN2014DN10510A (2)	2012-07-09	2015-08-21	Genentech Inc
US20140030280A1 (en)	2012-07-09	2014-01-30	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates
EP2869851A1 (en)	2012-07-09	2015-05-13	Genentech, Inc.	Immunoconjugates comprising anti-cd22 antibodies
KR20150030698A (ko)	2012-07-09	2015-03-20	제넨테크, 인크.	항-cd79b 항체를 포함하는 면역접합체
LT3495387T (lt)	2012-07-13	2021-11-25	Roche Glycart Ag	Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CN112587671A (zh)	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
JP6560120B2 (ja)	2012-08-02	2019-08-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｅｃｌ製造用の新規ビス−イリジウム錯体
CN104822696B (zh)	2012-08-02	2017-09-22	霍夫曼-拉罗奇有限公司	用于ecl的新型铱基配合物
CA2879087C (en)	2012-08-02	2020-10-27	F. Hoffmann-La Roche Ag	Iridium-based complexes for ecl
WO2014019709A2 (en)	2012-08-02	2014-02-06	Roche Diagnostics Gmbh	New iridium-based complexes for ecl
JP6255017B2 (ja)	2012-08-02	2017-12-27	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｅｃｌ用の新規イリジウムベース錯体
AR092044A1 (es)	2012-08-07	2015-03-18	Roche Glycart Ag	Inmunoterapia mejorada
CA2876285A1 (en)	2012-08-08	2014-02-13	Roche Glycart Ag	Interleukin-10 fusion proteins and uses thereof
EP2882775B1 (en)	2012-08-09	2018-02-14	Roche Glycart AG	Asgpr antibodies and uses thereof
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en)	2012-08-21	2014-02-27	Academia Sinica	Benzocyclooctyne compounds and uses thereof
CA2890346A1 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
MX2015005757A (es)	2012-11-08	2015-11-18	Hoffmann La Roche	Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
SG10201700488QA (en)	2012-11-13	2017-02-27	Genentech Inc	Anti-hemagglutinin antibodies and methods of use
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
EP2945652B1 (en)	2013-01-18	2021-07-07	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
WO2014114595A1 (en)	2013-01-23	2014-07-31	Roche Glycart Ag	Predictive biomarker for cancer treatment with adcc-enhanced antibodies
EP2958592A1 (en)	2013-02-22	2015-12-30	F. Hoffmann-La Roche AG	Methods of treating cancer and preventing drug resistance
RU2015140921A (ru)	2013-02-26	2017-04-03	Роше Гликарт Аг	Антитела к mcsp
CN105143270B (zh)	2013-02-26	2019-11-12	罗切格利卡特公司	双特异性t细胞活化抗原结合分子
CA2896359A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
MX375359B (es)	2013-02-26	2025-03-06	Roche Glycart Ag	Moléculas biespecíficas de unión a antígeno activadoras de células t.
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
PL2968467T3 (pl)	2013-03-13	2020-10-19	F. Hoffmann-La Roche Ag	Preparaty o zmniejszonym utlenianiu
CN110538322A (zh)	2013-03-13	2019-12-06	豪夫迈·罗氏有限公司	抗体配制剂
AR095398A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida
US10653779B2 (en)	2013-03-13	2020-05-19	Genentech, Inc.	Formulations with reduced oxidation
IL269947B (en)	2013-03-13	2022-08-01	Genentech Inc	Formulations with reduced oxidation
KR20150127216A (ko)	2013-03-14	2015-11-16	제넨테크, 인크.	암의 치료 및 암 약물 내성의 예방 방법
JP2016515132A (ja)	2013-03-14	2016-05-26	ジェネンテック，インコーポレイテッド	Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
AU2014244424A1 (en)	2013-03-14	2015-08-27	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
SG10201706210WA (en)	2013-03-15	2017-09-28	Genentech Inc	Compositions and methods for diagnosis and treatment of hepatic cancers
EP2970471A2 (en)	2013-03-15	2016-01-20	F. Hoffmann-La Roche AG	Anti-crth2 antibodies and their use
KR102389677B1 (ko)	2013-03-15	2022-04-21	제넨테크, 인크.	Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CN105143258B (zh)	2013-03-15	2020-06-23	Ac免疫有限公司	抗Tau抗体和使用方法
AU2014240083C1 (en)	2013-03-15	2019-10-24	Celgene Corporation	Modified T lymphocytes
WO2014144850A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
EP2968548B1 (en)	2013-03-15	2020-09-09	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the generation and use of conformation-specific antibodies
EP2968544A4 (en)	2013-03-15	2016-10-12	Hoffmann La Roche	CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
WO2014189973A2 (en)	2013-05-20	2014-11-27	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
EP3013365B1 (en)	2013-06-26	2019-06-05	Academia Sinica	Rm2 antigens and use thereof
WO2014210564A1 (en)	2013-06-27	2014-12-31	Academia Sinica	Glycan conjugates and use thereof
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
US10456470B2 (en)	2013-08-30	2019-10-29	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en)	2013-08-30	2020-04-14	Genentech, Inc.	Combination therapy for the treatment of glioblastoma
US9782476B2 (en)	2013-09-06	2017-10-10	Academia Sinica	Human iNKT cell activation using glycolipids with altered glycosyl groups
AU2014391422A1 (en)	2013-09-17	2015-12-17	Obi Pharma, Inc.	Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
WO2015042108A1 (en)	2013-09-17	2015-03-26	Genentech, Inc.	Methods of using anti-lgr5 antibodies
EP3049437A1 (en)	2013-09-27	2016-08-03	F. Hoffmann-La Roche AG	Thermus thermophilus slyd fkbp domain specific antibodies
MX375378B (es)	2013-09-27	2025-03-06	Genentech Inc	Formulaciones de anticuerpos anti-pdl1.
KR20160068855A (ko)	2013-10-11	2016-06-15	제넨테크, 인크.	Nsp4 억제제 및 사용 방법
KR20160044060A (ko)	2013-10-11	2016-04-22	에프. 호프만-라 로슈 아게	다중특이적 도메인 교환된 통상의 가변 경쇄 항체
CN105744954B (zh)	2013-10-18	2021-03-05	豪夫迈·罗氏有限公司	抗rspo2和/或抗rspo3抗体及其用途
SG11201603127WA (en)	2013-10-23	2016-05-30	Genentech Inc	Methods of diagnosing and treating eosinophilic disorders
CA2924268C (en)	2013-11-21	2021-05-18	F. Hoffmann-La Roche Ag	Anti-alpha-synuclein antibodies and methods of use
EA201691214A1 (ru)	2013-12-13	2016-12-30	Дженентек, Инк.	Антитела к cd33 и иммуноконъюгаты
AU2014364606A1 (en)	2013-12-17	2016-07-07	Genentech, Inc.	Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015095404A2 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
UA129760C2 (uk)	2013-12-17	2025-07-30	Дженентек, Інк.	Анти-cd3 антитіло та спосіб його застосування
HRP20200384T1 (hr)	2013-12-20	2020-06-12	F. Hoffmann - La Roche Ag	Humanizirana anti-tau(ps422) protutijela i načini uporabe
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
MX373856B (es)	2014-01-03	2020-03-25	Hoffmann La Roche	Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
CA2933384A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2932547C (en)	2014-01-06	2023-05-23	F. Hoffmann-La Roche Ag	Monovalent blood brain barrier shuttle modules
CN105899539B (zh)	2014-01-10	2021-11-09	博笛生物科技有限公司	用于免疫疗法的化合物和组合物
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
CA2937123A1 (en)	2014-01-16	2015-07-23	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US20170043034A1 (en)	2014-01-24	2017-02-16	Genentech, Inc.	Methods of using anti-steap1 antibodies and immunoconjugates
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
RU2724190C2 (ru)	2014-02-08	2020-06-23	Дженентек, Инк.	Способы лечения болезни альцгеймера
SG11201606490YA (en)	2014-02-08	2016-09-29	Genentech Inc	Methods of treating alzheimer's disease
PL3105253T3 (pl)	2014-02-12	2018-12-31	F. Hoffmann-La Roche Ag	Przeciwciała anty-Jagged1 i sposoby stosowania
JP2017507939A (ja)	2014-02-21	2017-03-23	ジェネンテック，インコーポレイテッド	抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
EP3116999B1 (en)	2014-03-14	2021-09-15	F. Hoffmann-La Roche AG	Methods and compositions for secretion of heterologous polypeptides
EP3119490B1 (en)	2014-03-21	2021-09-08	F. Hoffmann-La Roche AG	In vitro prediction of in vivo half-life of antibodies
WO2015140591A1 (en)	2014-03-21	2015-09-24	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
EP3122900A1 (en)	2014-03-24	2017-02-01	F. Hoffmann-La Roche AG	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
EP3126394B1 (en)	2014-03-31	2019-10-30	F.Hoffmann-La Roche Ag	Anti-ox40 antibodies and methods of use
RU2016142476A (ru)	2014-03-31	2018-05-07	Дженентек, Инк.	Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
MX388380B (es)	2014-04-18	2025-03-19	Acceleron Pharma Inc	Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
NZ725201A (en)	2014-04-25	2018-05-25	Bluebird Bio Inc	Improved methods for manufacturing adoptive cell therapies
LT3134432T (lt)	2014-04-25	2020-04-10	Bluebird Bio, Inc.	Mnd promotorius chimerinių antigenų receptoriams
DK3140653T3 (da)	2014-05-08	2022-06-20	Novodiax Inc	Direkte immunhistokemianalyse
WO2015179658A2 (en)	2014-05-22	2015-11-26	Genentech, Inc.	Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko)	2014-05-23	2017-01-11	제넨테크, 인크.	MiT 바이오마커 및 그의 사용 방법
CA2950423A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko)	2014-05-27	2023-03-21	아카데미아 시니카	항-ｈｅｒ2 글리코항체 및 이의 용도
KR20170003720A (ko)	2014-05-27	2017-01-09	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
SI3151672T1 (sl)	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
BR112016028838A2 (pt)	2014-06-11	2017-10-24	Genentech Inc	anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
WO2015192111A1 (en)	2014-06-13	2015-12-17	Acceleron Pharma, Inc.	Methods and compositions for treating ulcers
KR20170026362A (ko)	2014-06-26	2017-03-08	에프. 호프만-라 로슈 아게	항-ｂｒｄｕ 항체 및 사용 방법
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016004370A1 (en)	2014-07-03	2016-01-07	Genentech, Inc.	Polypeptide expression systems
CN105233291A (zh)	2014-07-09	2016-01-13	博笛生物科技有限公司	用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B2 (en)	2014-07-09	2026-04-08	Birdie Biopharmaceuticals Inc.	Anti-pd-l1 combinations for treating tumors
CA2952315A1 (en)	2014-07-11	2016-01-14	Genentech, Inc.	Notch pathway inhibition
ES2916923T3 (es)	2014-07-11	2022-07-06	Ventana Med Syst Inc	Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
WO2016011052A1 (en)	2014-07-14	2016-01-21	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
MX2017001079A (es)	2014-07-24	2017-09-12	Bluebird Bio Inc	Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
JP6464255B2 (ja)	2014-08-04	2019-02-06	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性ｔ細胞活性化抗原結合分子
WO2016033331A1 (en)	2014-08-28	2016-03-03	Bioatla, Llc	Conditionally active chimeric antigen receptors for modified t-cells
CN112587672A (zh)	2014-09-01	2021-04-02	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1结合物
CA2960712A1 (en)	2014-09-08	2016-03-17	Academia Sinica	Human inkt cell activation using glycolipids
LT3191135T (lt)	2014-09-12	2020-11-25	Genentech, Inc.	Anti-her2 antikūnai ir imunokonjugatai
JP6943760B2 (ja)	2014-09-12	2021-10-06	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及び免疫複合体
KR20170066421A (ko)	2014-09-12	2017-06-14	제넨테크, 인크.	항-cll-1 항체 및 면역접합체
JP7072384B2 (ja)	2014-09-15	2022-05-20	ジェネンテック，インコーポレイテッド	抗体製剤
HK1243629A1 (zh)	2014-09-17	2018-07-20	基因泰克公司	包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
PT3262071T (pt)	2014-09-23	2020-06-16	H Hoffnabb La Roche Ag	Métodos de utilização de imunoconjugados anti-cd79b
WO2016059113A1 (en)	2014-10-14	2016-04-21	Deutsches Krebsforschungszentrum	Norovirus antibodies
US9732148B2 (en)	2014-10-16	2017-08-15	Genentech, Inc.	Anti-α-synuclein antibodies and methods of use
MX2017005751A (es)	2014-11-03	2018-04-10	Genentech Inc	Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EP3215850B1 (en)	2014-11-03	2019-07-03	F. Hoffmann-La Roche AG	Assays for detecting t cell immune subsets and methods of use thereof
MX382952B (es)	2014-11-05	2025-03-13	Genentech Inc	Métodos de producción de proteínas de cadena doble en bacterias.
US10112994B2 (en)	2014-11-05	2018-10-30	Genentech, Inc.	Methods of producing two chain proteins in bacteria
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
KR20170072343A (ko)	2014-11-06	2017-06-26	제넨테크, 인크.	Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
TWI705976B (zh)	2014-11-10	2020-10-01	美商建南德克公司	抗介白素-33抗體及其用途
EP3217787B1 (en)	2014-11-10	2019-04-17	F.Hoffmann-La Roche Ag	Animal model for nephropathy and agents for treating the same
CR20170194A (es)	2014-11-14	2017-07-10	Hoffmann La Roche	Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
MX2017006320A (es)	2014-11-17	2017-08-10	Genentech Inc	Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
EP3221361B1 (en)	2014-11-19	2021-04-21	Genentech, Inc.	Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081639A1 (en)	2014-11-19	2016-05-26	Genentech, Inc.	Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221362B1 (en)	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies and methods of use
DK3221355T3 (da)	2014-11-20	2020-12-07	Hoffmann La Roche	Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221357T1 (sl)	2014-11-20	2020-09-30	F. Hoffmann-La Roche Ag	Pogoste lahke verige in načini uporabe
WO2021173560A1 (en)	2020-02-24	2021-09-02	Immatics US, Inc.	Methods for expanding t cells for the treatment of cancer and related malignancies
CN107001482B (zh)	2014-12-03	2021-06-15	豪夫迈·罗氏有限公司	多特异性抗体
MA41119A (fr)	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA40938A (fr)	2014-12-05	2017-10-11	Hoffmann La Roche	Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
RU2017120039A (ru)	2014-12-10	2019-01-10	Дженентек, Инк.	Антитела к рецепторам гематоэнцефалического барьера и способы их применения
EA036379B1 (ru)	2014-12-12	2020-11-02	Блубёрд Био, Инк.	Химерные антигенные рецепторы к bcma
ES2761427T3 (es)	2014-12-18	2020-05-19	Hoffmann La Roche	Procedimientos para reducir interferencias
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107207607B (zh)	2014-12-19	2021-05-04	中外制药株式会社	抗-c5抗体及使用方法
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
CN107428823B (zh)	2015-01-22	2021-10-26	中外制药株式会社	两种以上抗-c5抗体的组合与使用方法
AU2015378564A1 (en)	2015-01-24	2017-07-13	Academia Sinica	Novel glycan conjugates and methods of use thereof
CA2973886A1 (en)	2015-01-30	2016-08-04	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2975875A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
CN114773470A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3271723A1 (en)	2015-03-16	2018-01-24	F. Hoffmann-La Roche AG	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10227392B2 (en)	2015-04-06	2019-03-12	Acceleron Pharma Inc.	ALK7:ActRIIB heteromultimers and uses thereof
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
CN107708733B (zh)	2015-04-07	2022-11-15	艾利妥	抗分拣蛋白抗体和其使用方法
AU2016246695A1 (en)	2015-04-07	2017-10-26	Genentech, Inc.	Antigen binding complex having agonistic activity and methods of use
CN113552350B (zh)	2015-04-21	2024-10-11	基因泰克公司	用于前列腺癌分析的组合物和方法
EP3286315B1 (en)	2015-04-24	2021-05-26	F. Hoffmann-La Roche AG	Methods of identifying bacteria comprising binding polypeptides
EP3778640A1 (en)	2015-05-01	2021-02-17	Genentech, Inc.	Masked anti-cd3 antibodies and methods of use
WO2016183104A1 (en)	2015-05-11	2016-11-17	Genentech, Inc.	Compositions and methods of treating lupus nephritis
RS61152B2 (sr)	2015-05-12	2024-06-28	Hoffmann La Roche	Terapeutski i dijagnostički postupci za lečenje raka
JP7144935B2 (ja)	2015-05-29	2022-09-30	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
EP3302467A4 (en)	2015-05-31	2019-01-02	Curegenix Corporation	Combination compositions for immunotherapy
EP3302552A1 (en)	2015-06-02	2018-04-11	H. Hoffnabb-La Roche Ag	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EP4465050A3 (en)	2015-06-05	2025-06-11	Genentech, Inc.	Anti-tau antibodies and methods of use
KR20180011839A (ko)	2015-06-08	2018-02-02	제넨테크, 인크.	항-ox40 항체를 이용한 암의 치료 방법
HK1251474A1 (zh)	2015-06-08	2019-02-01	豪夫迈‧罗氏有限公司	使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
JP7376977B2 (ja)	2015-06-12	2023-11-09	アレクトルエルエルシー	抗ｃｄ３３抗体及びその使用方法
JP7497953B2 (ja)	2015-06-12	2024-06-11	アレクトルエルエルシー	抗ｃｄ３３抗体及びその使用方法
CN108064246A (zh)	2015-06-15	2018-05-22	基因泰克公司	抗体和免疫结合物
TWI731861B (zh)	2015-06-16	2021-07-01	美商建南德克公司	FcRH5之人源化及親和力成熟抗體及使用方法
EP3310378B1 (en)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1 antibodies and methods of use
EP3916018A1 (en)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3 antibodies and methods of use
JP6896650B2 (ja)	2015-06-17	2021-06-30	ジェネンテック，インコーポレイテッド	Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
CN107810196B (zh)	2015-06-24	2021-11-05	豪夫迈·罗氏有限公司	人源化的抗-Tau(pS422)抗体和使用方法
WO2016207091A1 (en)	2015-06-24	2016-12-29	F. Hoffmann-La Roche Ag	Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
KR20180021864A (ko)	2015-06-29	2018-03-05	제넨테크, 인크.	장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
CA3162816A1 (en)	2015-06-29	2017-01-05	Ventana Medical Systems, Inc.	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
HK1256638A1 (zh)	2015-08-04	2019-09-27	Acceleron Pharma Inc.	用於治疗骨髓增生性病症的方法
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3130922A1 (en)	2015-08-11	2017-02-15	Roche Diagnostics GmbH	Alkaline pretreatment of parvoviruses for immunoassays
ES2734807T3 (es)	2015-08-20	2019-12-12	Hoffmann La Roche	Inmunoensayo basado en partículas que usa un agente de unión específica a un analito pegilado
JP6920786B2 (ja)	2015-08-26	2021-08-18	ドイチェスクレブスフォルシュンクスツェントルム	免疫ウイルス療法のためのｒｎａウイルス
EP3341415B1 (en)	2015-08-28	2021-03-24	H. Hoffnabb-La Roche Ag	Anti-hypusine antibodies and uses thereof
US11279769B2 (en)	2015-08-31	2022-03-22	Helixmith Co., Ltd	Anti-Sialyl Tn chimeric antigen receptors
WO2017040932A1 (en)	2015-09-04	2017-03-09	Primatope Therapeutics Inc.	Humanized anti-cd40 antibodies and uses thereof
KR20180050339A (ko)	2015-09-04	2018-05-14	오비아이 파머 인코퍼레이티드	글리칸 어레이 및 사용 방법
KR20230079500A (ko)	2015-09-18	2023-06-07	추가이 세이야쿠 가부시키가이샤	Il-8에 결합하는 항체 및 그의 사용
JP6904947B2 (ja)	2015-09-22	2021-07-21	スプリングバイオサイエンスコーポレーション	抗ｏｘ４０抗体及びその診断用途
RU2763916C2 (ru)	2015-09-23	2022-01-11	Дженентек, Инк.	Оптимизированные варианты анти-vegf антител
AU2016326738B2 (en)	2015-09-24	2023-08-31	Abvitro Llc	HIV antibody compositions and methods of use
CA2994858C (en)	2015-09-25	2024-01-23	Genentech, Inc.	Anti-tigit antibodies and methods of use
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US20180282410A1 (en)	2015-10-02	2018-10-04	Hoffmann-La Roche Inc.	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055388A2 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific t cell activating antigen binding molecules
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
EP3356407B1 (en)	2015-10-02	2021-11-03	F. Hoffmann-La Roche AG	Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CR20180151A (es)	2015-10-02	2018-05-25	Hoffmann La Roche	Antcuierpos anti-pd1 y métodos de uso
CA2996902C (en)	2015-10-02	2020-06-02	Genentech, Inc.	Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PE20240096A1 (es)	2015-10-02	2024-01-18	Hoffmann La Roche	Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
NZ739090A (en)	2015-10-02	2025-06-27	Hoffmann La Roche	Bispecific antibodies specific for pd1 and tim3
US20170096485A1 (en)	2015-10-02	2017-04-06	Hoffmann-La Roche Inc.	Bispecific t cell activating antigen binding molecules
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
EP3356410B1 (en)	2015-10-02	2021-10-20	F. Hoffmann-La Roche AG	Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
WO2017060144A1 (en)	2015-10-07	2017-04-13	F. Hoffmann-La Roche Ag	Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3362100B1 (en)	2015-10-16	2022-06-22	Genentech, Inc.	Hindered disulfide drug conjugates
EP3365025B1 (en)	2015-10-20	2020-07-15	Genentech, Inc.	Calicheamicin-antibody-drug conjugates and methods of use
US10954500B2 (en)	2015-10-23	2021-03-23	Fred Hutchinson Cancer Research Center	Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
AU2016344665C1 (en)	2015-10-29	2023-07-27	F. Hoffmann-La Roche Ag	Anti-variant Fc-region antibodies and methods of use
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
KR102162324B1 (ko)	2015-10-30	2020-10-07	제넨테크, 인크.	항-HtrA1 항체 및 이의 사용 방법
US10407510B2 (en)	2015-10-30	2019-09-10	Genentech, Inc.	Anti-factor D antibodies and conjugates
US11123430B2 (en)	2015-11-04	2021-09-21	Acceleron Pharma Inc.	Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3371217B1 (en)	2015-11-08	2025-06-11	F. Hoffmann-La Roche AG	Methods of screening for multispecific antibodies
CA3005975A1 (en)	2015-11-23	2017-06-01	Acceleron Pharma Inc.	Methods for treating eye disorders
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
EP3178848A1 (en)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP4026848A1 (en)	2015-12-09	2022-07-13	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing the cytokine release syndrome
IL259256B2 (en)	2015-12-18	2023-02-01	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
TWI605057B (zh)	2015-12-18	2017-11-11	中外製藥股份有限公司	抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
HRP20250951T1 (hr)	2015-12-30	2025-10-10	F. Hoffmann-La Roche Ag	Formulacije sa smanjenom razgradnjom polisorbata
EP3397243A1 (en)	2015-12-30	2018-11-07	H. Hoffnabb-La Roche Ag	Use of tryptophan derivatives for protein formulations
JP6949030B2 (ja)	2016-01-08	2021-10-13	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
BR112018014762A2 (pt)	2016-01-20	2018-12-26	Genentech Inc	método de tratamento da doença de alzheimer (da) precoce
US10344067B2 (en)	2016-02-25	2019-07-09	Deutsches Krebsforschungszentrum	RNA viruses expressing IL-12 for immunovirotherapy
US10982136B2 (en)	2016-02-26	2021-04-20	The Regents Of The University Of California	Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
JP7157981B2 (ja)	2016-03-07	2022-10-21	チャールストンファーマ，エルエルシー	抗ヌクレオリン抗体
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
CN116196412A (zh)	2016-03-15	2023-06-02	中外制药株式会社	使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
CR20180453A (es)	2016-03-22	2018-12-05	Hoffmann La Roche	Moleculas biespecíficas de células t activadas por proteasas
US20170315132A1 (en)	2016-03-25	2017-11-02	Genentech, Inc.	Multiplexed total antibody and antibody-conjugated drug quantification assay
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
EP3231813A1 (en)	2016-03-29	2017-10-18	F. Hoffmann-La Roche AG	Trimeric costimulatory tnf family ligand-containing antigen binding molecules
AU2017239637A1 (en)	2016-03-29	2018-11-15	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
WO2017177013A1 (en)	2016-04-06	2017-10-12	Acceleron Pharma Inc.	Alk7 antagonists and uses thereof
EP3443004A1 (en)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3 antibodies and methods of use
WO2017180993A1 (en)	2016-04-14	2017-10-19	Bluebird Bio, Inc.	Salvage chimeric antigen receptor systems
PL3443012T3 (pl)	2016-04-15	2026-04-20	Bioatla, Inc.	Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania
CN109154613A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
AU2017248766A1 (en)	2016-04-15	2018-11-01	Genentech, Inc.	Methods for monitoring and treating cancer
CN109379889A (zh)	2016-04-22	2019-02-22	台湾浩鼎生技股份有限公司	通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
EP3243836A1 (en)	2016-05-11	2017-11-15	F. Hoffmann-La Roche AG	C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194441A1 (en)	2016-05-11	2017-11-16	F. Hoffmann-La Roche Ag	Modified anti-tenascin antibodies and methods of use
EP3455254B1 (en)	2016-05-11	2021-07-07	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (en)	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN116751298A (zh)	2016-05-13	2023-09-15	生物蛋白有限公司	抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
EP3458101B1 (en)	2016-05-20	2020-12-30	H. Hoffnabb-La Roche Ag	Protac antibody conjugates and methods of use
EP3465221B1 (en)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7044721B2 (ja)	2016-05-31	2022-03-30	エフ．ホフマン－ラロシュアーゲー	Ｈｃｖコア抗原の迅速な検出のための前処理法
EP3465217B1 (en)	2016-05-31	2025-09-03	Roche Diagnostics GmbH	Method for serological detection of viral antigens
TW201902512A (zh)	2016-06-02	2019-01-16	瑞士商赫孚孟拉羅股份公司	治療方法
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US10639378B2 (en)	2016-06-06	2020-05-05	Genentech, Inc.	Silvestrol antibody-drug conjugates and methods of use
JP6805272B2 (ja)	2016-06-15	2020-12-23	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	改善されたｄダイマーアッセイ較正
KR102306744B1 (ko)	2016-06-17	2021-09-28	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
EP3475298A1 (en)	2016-06-24	2019-05-01	H. Hoffnabb-La Roche Ag	Anti-polyubiquitin multispecific antibodies
US20190233534A1 (en)	2016-07-14	2019-08-01	Fred Hutchinson Cancer Research Center	Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
HRP20210694T1 (hr)	2016-07-15	2021-09-17	Acceleron Pharma, Inc.	Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
PL3490582T3 (pl)	2016-07-27	2024-09-23	Acceleron Pharma Inc.	Kompozycje do zastosowania w leczeniu mielofibrozy
KR20230117482A (ko)	2016-07-27	2023-08-08	오비아이 파머 인코퍼레이티드	면역원성/치료 글리칸 조성물 및 그의 용도
KR102591955B1 (ko)	2016-07-29	2023-10-19	추가이 세이야쿠 가부시키가이샤	증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
WO2018023121A1 (en)	2016-07-29	2018-02-01	Obi Pharma, Inc.	Human antibodies, pharmaceutical compositions and methods
TWI693940B (zh)	2016-08-05	2020-05-21	日商中外製藥股份有限公司	Ｉｌ-８相關疾病之治療用或預防用組成物
US11046776B2 (en)	2016-08-05	2021-06-29	Genentech, Inc.	Multivalent and multiepitopic antibodies having agonistic activity and methods of use
WO2018029124A1 (en)	2016-08-08	2018-02-15	F. Hoffmann-La Roche Ag	Therapeutic and diagnostic methods for cancer
EP4282877A3 (en)	2016-08-10	2024-02-21	Legend Biotech Ireland Limited	Chimeric antigen receptors targeting bcma and methods of use thereof
WO2018031662A1 (en)	2016-08-11	2018-02-15	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
AU2017311585A1 (en)	2016-08-12	2019-02-28	Genentech, Inc.	Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
EP3500594A4 (en)	2016-08-22	2020-03-11	Cho Pharma Inc.	ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
EP3504155B1 (en)	2016-08-25	2023-03-08	Roche Diagnostics GmbH	Multifunctionalized silicon nanoparticles and uses thereof in electrochemiluminescence based detection methods
ES3015117T3 (en)	2016-08-29	2025-04-29	Fred Hutchinson Cancer Center	Chelating platform for delivery of radionuclides
EP3509595B1 (en)	2016-09-06	2022-11-02	The Regents of The University of California	Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
WO2018049261A1 (en)	2016-09-09	2018-03-15	Icellhealth Consulting Llc	Oncolytic virus expressing immune checkpoint modulators
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR102557643B1 (ko)	2016-09-23	2023-07-20	제넨테크, 인크.	아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
CA3038670A1 (en)	2016-09-29	2018-04-05	The Regents Of The University Of California	Chelating molecules
AU2017335839A1 (en)	2016-09-29	2019-04-18	Genentech, Inc.	Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
EP4290532A3 (en)	2016-09-29	2024-03-20	The Regents of the University of California	Separation of metal ions by liquid-liquid extraction
ES2897217T3 (es)	2016-09-30	2022-02-28	Hoffmann La Roche	Anticuerpos biespecíficos frente a p95HER2
JP2019529509A (ja)	2016-10-05	2019-10-17	アクセレロンファーマインコーポレーテッド	腎臓疾患を治療するための組成物および方法
EP3522933B1 (en)	2016-10-05	2021-12-15	F. Hoffmann-La Roche AG	Methods for preparing antibody drug conjugates
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
JP6949468B2 (ja)	2016-10-17	2021-10-13	ルプレヒト−カールス−ウニベルジテートハイデルベルク	腫瘍抗原をコードする麻疹ウイルス
WO2018077783A1 (en)	2016-10-24	2018-05-03	Roche Diagnostics Gmbh	Immobilized analytes
EP3532091A2 (en)	2016-10-29	2019-09-04	H. Hoffnabb-La Roche Ag	Anti-mic antibidies and methods of use
KR20240005168A (ko)	2016-11-04	2024-01-11	2세븐티 바이오, 인코포레이티드	항-bcma car t 세포 조성물
WO2018093821A1 (en)	2016-11-15	2018-05-24	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL266628B2 (en)	2016-11-17	2024-06-01	Bluebird Bio Inc	TGFBeta signal converter
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
TWI822055B (zh)	2016-11-21	2023-11-11	台灣浩鼎生技股份有限公司	共軛生物分子、醫藥組成物及方法
CN117820467A (zh)	2016-12-07	2024-04-05	基因泰克公司	抗tau抗体和使用方法
MA48595A (fr)	2016-12-07	2020-03-18	Ac Immune Sa	Anticorps anti-tau et leurs méthodes d'utilisation
EP3555620A1 (en)	2016-12-13	2019-10-23	H. Hoffnabb-La Roche Ag	Method to determine the presence of a target antigen in a tumor sample
WO2018114754A1 (en)	2016-12-19	2018-06-28	F. Hoffmann-La Roche Ag	Combination therapy with targeted 4-1bb (cd137) agonists
AU2017384126B2 (en)	2016-12-20	2025-01-23	F. Hoffmann-La Roche Ag	Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
CN108239150A (zh)	2016-12-24	2018-07-03	信达生物制药(苏州)有限公司	抗pcsk9抗体及其用途
CN110088129A (zh)	2016-12-27	2019-08-02	豪夫迈·罗氏有限公司	新的生物素特异性单克隆抗体及其用途
BR112019010915A2 (pt)	2016-12-27	2019-10-01	Hoffmann La Roche	anticorpo monoclonal, métodos para medir um analito em uma amostra e para produzir um anticorpo, uso de um anticorpo, kit de teste de imunoensaio e imunógeno
EP3562845B1 (en)	2016-12-27	2025-10-01	F. Hoffmann-La Roche AG	Novel biotin-specific monoclonal antibody and use thereof
BR112019013189A2 (pt)	2017-01-03	2019-12-10	Hoffmann La Roche	moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
WO2018141768A1 (en)	2017-02-02	2018-08-09	Roche Diagnostics Gmbh	Immunoassay using at least two pegylated analyte-specific binding agents
KR20240046168A (ko)	2017-02-03	2024-04-08	액티코어 바이오테크	항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
PE20191548A1 (es)	2017-02-10	2019-10-24	Genentech Inc	Anticuerpos contra triptasa, composiciones de estos y usos de estos
CN110546277B (zh)	2017-03-01	2024-06-11	豪夫迈·罗氏有限公司	用于癌症的诊断和治疗方法
CA3056248A1 (en)	2017-03-22	2018-09-27	Genentech, Inc.	Optimized antibody compositions for treatment of ocular disorders
SG10202107829YA (en)	2017-03-22	2021-08-30	Genentech Inc	Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN108623686A (zh)	2017-03-25	2018-10-09	信达生物制药(苏州)有限公司	抗ox40抗体及其用途
ES3010117T3 (en)	2017-03-27	2025-04-01	Hoffmann La Roche	Improved antigen binding receptors
TW201900672A (zh)	2017-03-27	2019-01-01	瑞士商赫孚孟拉羅股份公司	改良之抗原結合受體型式
KR20190133162A (ko)	2017-03-28	2019-12-02	제넨테크, 인크.	신경퇴행성 질병의 치료 방법
EP3601345A1 (en)	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3601346A1 (en)	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Trimeric antigen binding molecules specific for a costimulatory tnf receptor
JP7148539B2 (ja)	2017-04-03	2022-10-05	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	免疫抱合体
SG11201909218RA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Antibodies binding to steap-1
RU2761377C2 (ru)	2017-04-03	2021-12-07	Ф. Хоффманн-Ля Рош Аг	Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
AU2018247796A1 (en)	2017-04-04	2019-08-29	F. Hoffmann-La Roche Ag	Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
TWI690538B (zh)	2017-04-05	2020-04-11	瑞士商赫孚孟拉羅股份公司	特異性結合至pd1至lag3的雙特異性抗體
SI3606954T1 (sl)	2017-04-05	2022-10-28	F. Hoffmann - La Roche Ag	Protitelesa proti LAG3
BR112019018051A2 (pt)	2017-04-12	2020-04-07	Hoffmann La Roche	método para produzir um composto, composto e substância
KR20190136076A (ko)	2017-04-13	2019-12-09	에프. 호프만-라 로슈 아게	암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
US12460208B2 (en)	2017-04-18	2025-11-04	Parr Biotechnology Co., Ltd.	Immunomodulatory polynucleotides and uses thereof
CN108728444A (zh)	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
SG11201909048TA (en)	2017-04-21	2019-11-28	Genentech Inc	Use of klk5 antagonists for treatment of a disease
EP3615572A1 (en)	2017-04-27	2020-03-04	Tesaro Inc.	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EP3625251A1 (en)	2017-05-15	2020-03-25	University Of Rochester	Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
EP3409322A1 (en)	2017-06-01	2018-12-05	F. Hoffmann-La Roche AG	Treatment method
WO2018224439A1 (en)	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-hsa antibodies
WO2018224441A1 (en)	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-cd3 antibodies
JP7247110B2 (ja)	2017-06-05	2023-03-28	ヌマブセラピューティクスアクチェンゲゼルシャフト	新規抗ｃｄ３抗体
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
KR102922386B1 (ko)	2017-07-21	2026-02-04	제넨테크, 인크.	암에 대한 치료 및 진단 방법
CN110869050B (zh)	2017-07-28	2024-07-02	豪夫迈·罗氏有限公司	双特异性抗体配制剂
KR102733407B1 (ko)	2017-08-03	2024-11-21	알렉터 엘엘씨	항-cd33 항체 및 이의 이용 방법
CN109422811A (zh)	2017-08-29	2019-03-05	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
EP3459970A1 (en)	2017-09-20	2019-03-27	Universität Heidelberg	Norovirus nanobodies
WO2019059411A1 (en)	2017-09-20	2019-03-28	Chugai Seiyaku Kabushiki Kaisha	DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
EP3459968A1 (en)	2017-09-20	2019-03-27	Numab Innovation AG	Novel stable antibody variable domain framework combinations
AR113142A1 (es)	2017-09-29	2020-01-29	Chugai Pharmaceutical Co Ltd	Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
EP3470429A1 (en)	2017-10-10	2019-04-17	Numab Innovation AG	Antibodies targeting pdl1 and methods of use thereof
CN111194323B (zh)	2017-10-10	2024-07-09	努玛治疗有限公司	多特异性抗体
AU2018348430B2 (en)	2017-10-10	2025-09-04	Numab Therapeutics AG	Antibodies targeting PDL1 and methods of use thereof
CN111183159B (zh)	2017-10-10	2024-09-03	努玛治疗有限公司	靶向cd137的抗体及其使用方法
EP3470428A1 (en)	2017-10-10	2019-04-17	Numab Innovation AG	Antibodies targeting cd137 and methods of use thereof
EP3470426A1 (en)	2017-10-10	2019-04-17	Numab Therapeutics AG	Multispecific antibody
KR20200067197A (ko)	2017-10-20	2020-06-11	에프. 호프만-라 로슈 아게	단일특이적 항체로부터 다중특이적 항체의 생성 방법
BR112020007736A2 (pt)	2017-10-30	2020-10-20	F. Hoffmann-La Roche Ag	composição e método de tratamento
KR20200084006A (ko)	2017-11-01	2020-07-09	에프. 호프만-라 로슈 아게	표적화된 ox40 작용제를 사용하는 병용 요법
BR112020006443A2 (pt)	2017-11-01	2020-09-29	F. Hoffmann-La Roche Ag	anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
WO2019086499A1 (en)	2017-11-01	2019-05-09	F. Hoffmann-La Roche Ag	Novel tnf family ligand trimer-containing antigen binding molecules
ES2984919T3 (es)	2017-11-06	2024-10-31	Hoffmann La Roche	Procedimientos diagnósticos y terapéuticos para el cáncer
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHOD OF USING
CA3079039A1 (en)	2017-12-14	2019-06-20	F. Hoffmann-La Roche Ag	Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
WO2019122046A1 (en)	2017-12-21	2019-06-27	F. Hoffmann-La Roche Ag	Universal reporter cell assay for specificity test of novel antigen binding moieties
SG11202005632SA (en)	2017-12-21	2020-07-29	Hoffmann La Roche	Antibodies binding to hla-a2/wt1
JP2021508246A (ja)	2017-12-21	2021-03-04	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
EP3502140A1 (en)	2017-12-21	2019-06-26	F. Hoffmann-La Roche AG	Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019126472A1 (en)	2017-12-22	2019-06-27	Genentech, Inc.	Use of pilra binding agents for treatment of a disease
CN115925943A (zh)	2017-12-27	2023-04-07	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
KR102845020B1 (ko)	2017-12-28	2025-08-12	난징 레전드 바이오테크 씨오., 엘티디.	Pd-l1에 대한 항체 및 변이체
WO2019129679A1 (en)	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
JP7490565B2 (ja)	2017-12-29	2024-05-27	アレクトルエルエルシー	抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3740507A4 (en)	2018-01-15	2022-08-24	Nanjing Legend Biotech Co., Ltd.	SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
EP3740505A1 (en)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispecific antibody that binds cd3 and another target
CN111630063A (zh)	2018-01-31	2020-09-04	豪夫迈·罗氏有限公司	稳定化的免疫球蛋白结构域
US20200354457A1 (en)	2018-01-31	2020-11-12	Hoffmann-La Roche Inc.	Bispecific antibodies comprising an antigen-binding site binding to lag3
CN111971301B (zh)	2018-01-31	2025-01-07	艾莱克特有限责任公司	抗ms4a4a抗体及其使用方法
AU2019214183B2 (en)	2018-02-01	2022-04-07	Innovent Biologics (Suzhou) Co., Ltd.	Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
JP7475275B2 (ja)	2018-02-08	2024-04-26	ジェネンテック，インコーポレイテッド	二重特異性抗原結合分子及びその使用方法
AU2019218128A1 (en)	2018-02-09	2020-09-17	Genentech, Inc.	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
EP3749682B1 (en)	2018-02-09	2025-09-24	Acceleron Pharma Inc.	Treating heterotopic ossification
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
WO2019166453A1 (en)	2018-03-01	2019-09-06	F. Hoffmann-La Roche Ag	Specificity assay for novel target antigen binding moieties
IL277174B2 (en)	2018-03-13	2025-12-01	Hoffmann La Roche	Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
TWI841551B (zh)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	使用靶向4-1bb (cd137)之促效劑的組合療法
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
MX394121B (es)	2018-03-14	2025-03-24	Surface Oncology Inc	Anticuerpos que se unen a cd39 y sus usos
CA3093729A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
HRP20260157T1 (hr)	2018-03-29	2026-03-27	F. Hoffmann - La Roche Ag	Moduliranje laktogene aktivnosti u stanicama sisavaca
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
EP3775902B1 (en)	2018-04-04	2023-02-22	F. Hoffmann-La Roche AG	Diagnostic assays to detect tumor antigens in cancer patients
WO2019192972A1 (en)	2018-04-04	2019-10-10	F. Hoffmann-La Roche Ag	Diagnostic assays to detect tumor antigens in cancer patients
CR20200459A (es)	2018-04-13	2020-11-11	Hoffmann La Roche	Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
EP3787678A1 (en)	2018-05-03	2021-03-10	University Of Rochester	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
WO2019217913A1 (en)	2018-05-10	2019-11-14	Sensei Biotherapeutics, Inc.	Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
JP7206297B2 (ja)	2018-05-18	2023-01-17	エフ．ホフマン－ラロシュアーゲー	大核酸の細胞内標的指向送達
EP3802602A1 (en)	2018-05-25	2021-04-14	Alector LLC	Anti-sirpa antibodies and methods of use thereof
EP3805400A4 (en)	2018-06-04	2022-06-29	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
EP3802619A1 (en)	2018-06-08	2021-04-14	F. Hoffmann-La Roche AG	Peptidic linker with reduced post-translational modification
US12247084B2 (en)	2018-06-14	2025-03-11	2Seventy Bio, Inc.	Anti-BCMA CAR antibodies, conjugates, and methods of use
JP2021527409A (ja)	2018-06-14	2021-10-14	ブルーバードバイオ，インコーポレイテッド	Ｃｄ７９ａキメラ抗原受容体
CN112585166A (zh)	2018-06-23	2021-03-30	豪夫迈·罗氏有限公司	用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
WO2020006176A1 (en)	2018-06-27	2020-01-02	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
CN112384532B (zh)	2018-06-29	2025-01-10	艾利妥	抗SIRP-β1抗体及其使用方法
EP3818083A2 (en)	2018-07-03	2021-05-12	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
WO2020007817A1 (en)	2018-07-04	2020-01-09	F. Hoffmann-La Roche Ag	Novel bispecific agonistic 4-1bb antigen binding molecules
CA3105813A1 (en)	2018-07-11	2020-01-16	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
TWI809147B (zh)	2018-07-13	2023-07-21	美商阿列克特有限責任公司	抗分揀蛋白抗體及其使用方法
US20210275589A1 (en)	2018-07-13	2021-09-09	Nanjing Legend Biotech Co. Ltd.	Co-receptor systems for treating infectious diseases
GB201811597D0 (en)	2018-07-16	2018-08-29	Hemogad Tech Ltd	Analyser
BR112021000673A2 (pt)	2018-07-18	2021-04-20	Genentech, Inc.	métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
BR112021000727A2 (pt)	2018-07-20	2021-04-13	Surface Oncology, Inc.	Composições anti-cd112r e métodos
MX2021000827A (es)	2018-08-03	2021-03-25	Chugai Pharmaceutical Co Ltd	Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
CA3106537A1 (en)	2018-08-08	2020-02-13	Genentech, Inc.	Use of tryptophan derivatives and l-methionine for protein formulation
EP3835321A4 (en)	2018-08-10	2022-11-02	Chugai Seiyaku Kabushiki Kaisha	ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
CN121248772A (zh)	2018-08-17	2026-01-02	Ab工作室有限公司	催化抗体和其使用方法
MX2021002299A (es)	2018-08-31	2021-04-28	Alector Llc	Anticuerpos de anti-cd33 y metodos para usarlos.
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
US12097219B2 (en)	2018-09-10	2024-09-24	Legend Biotech Ireland Limited	Single-domain antibodies against CLL1 and constructs thereof
AR114732A1 (es)	2018-09-18	2020-10-07	Hoffmann La Roche	Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
JP2022501332A (ja)	2018-09-19	2022-01-06	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法および診断方法
KR102739487B1 (ko)	2018-09-21	2024-12-10	제넨테크, 인크.	3중-음성 유방암에 대한 진단 방법
NZ773887A (en)	2018-10-01	2024-11-29	Hoffmann La Roche	Bispecific antigen binding molecules comprising anti-fap clone 212
EP3861025A1 (en)	2018-10-01	2021-08-11	F. Hoffmann-La Roche AG	Bispecific antigen binding molecules with trivalent binding to cd40
EP3636320A1 (en)	2018-10-09	2020-04-15	Numab Therapeutics AG	Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh)	2018-10-09	2024-04-21	瑞士商Ｎｕｍａｂ治療公司	靶向cd137的抗體及其使用方法
TW202028244A (zh)	2018-10-09	2020-08-01	美商建南德克公司	用於確定突觸形成之方法及系統
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
JP7708662B2 (ja)	2018-10-24	2025-07-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	コンジュゲート化された化学的分解誘導物質および使用方法
WO2020096959A1 (en)	2018-11-05	2020-05-14	Genentech, Inc.	Methods of producing two chain proteins in prokaryotic host cells
KR102624804B1 (ko)	2018-11-16	2024-01-12	에프. 호프만-라 로슈 아게	결합 쌍의 부재를 갖는 스트렙타비딘 코팅된 고체상
KR20210100668A (ko)	2018-12-06	2021-08-17	제넨테크, 인크.	항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
EP3894427A1 (en)	2018-12-10	2021-10-20	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
SG10202105788SA (en)	2018-12-21	2021-06-29	Hoffmann La Roche	Antibodies binding to cd3
TWI861039B (zh)	2018-12-21	2024-11-11	瑞士商赫孚孟拉羅股份公司	靶向腫瘤之促效cd28抗原結合分子
WO2020132231A1 (en)	2018-12-21	2020-06-25	Genentech, Inc.	Methods of producing polypeptides using a cell line resistant to apoptosis
US11884719B2 (en)	2018-12-21	2024-01-30	23Andme, Inc.	Anti-IL-36 antibodies and methods of use thereof
JP2022513495A (ja)	2018-12-21	2022-02-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
EP3906415B1 (en)	2019-01-03	2026-04-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
TW202515617A (zh)	2019-01-14	2025-04-16	美商建南德克公司	用於癌症療法之rna分子
WO2020154410A1 (en)	2019-01-23	2020-07-30	Genentech, Inc.	Methods of producing multimeric proteins in eukaryotic host cells
WO2020153467A1 (ja)	2019-01-24	2020-07-30	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
JP7525499B2 (ja)	2019-01-31	2024-07-30	ヌマブセラピューティクスアクチェンゲゼルシャフト	ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en)	2019-01-31	2020-08-05	Numab Therapeutics AG	Antibodies targeting il-17a and methods of use thereof
EP3921443A1 (en)	2019-02-08	2021-12-15	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for cancer
JP7710373B2 (ja)	2019-02-21	2025-07-18	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020169698A1 (en)	2019-02-21	2020-08-27	F. Hoffmann-La Roche Ag	Sensitization of cancer cells to tnf by bet inhibition
AU2020224681A1 (en)	2019-02-21	2021-09-16	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
KR20210133237A (ko)	2019-02-27	2021-11-05	제넨테크, 인크.	항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
WO2020180591A1 (en)	2019-03-01	2020-09-10	Allogene Therapeutics, Inc.	Dll3 targeting chimeric antigen receptors and binding agents
MX2021010565A (es)	2019-03-08	2021-10-13	Genentech Inc	Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
TW202100556A (zh)	2019-03-14	2021-01-01	美商建南德克公司	使用her2 t細胞依賴性雙特異性抗體之治療
CN114423863A (zh)	2019-03-18	2022-04-29	德国癌症研究中心	用于细胞遗传修饰的表达构建体
JP2022525275A (ja)	2019-03-28	2022-05-12	エービーストゥーディオインコーポレイテッド	ヘテロ多量体タンパク質及びその使用法
US12291562B2 (en)	2019-04-01	2025-05-06	Rush University Medical Center	Reagents and assays using modified integrin domains
WO2020208049A1 (en)	2019-04-12	2020-10-15	F. Hoffmann-La Roche Ag	Bispecific antigen binding molecules comprising lipocalin muteins
WO2020208124A1 (en)	2019-04-12	2020-10-15	F. Hoffmann-La Roche Ag	Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
BR112021020867A2 (pt)	2019-04-19	2022-01-04	Genentech Inc	Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
KR20220004028A (ko)	2019-04-26	2022-01-11	알로젠 테라퓨틱스 인코포레이티드	동종 car t 세포를 제조하는 방법
CA3135531A1 (en)	2019-04-30	2020-11-05	Daniel Getts	Engineered chimeric fusion protein compositions and methods of use thereof
CN114269376A (zh)	2019-05-03	2022-04-01	豪夫迈·罗氏有限公司	用抗pd-l1抗体治疗癌症的方法
KR20220007136A (ko)	2019-05-14	2022-01-18	제넨테크, 인크.	소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
MX2021013441A (es)	2019-05-15	2021-12-10	Chugai Pharmaceutical Co Ltd	Molecula de union a antigenos, composicion farmaceutica y metodo.
US20200392229A1 (en)	2019-06-11	2020-12-17	Alector Llc	Methods of use of anti-sortilin antibodies
JP2022538075A (ja)	2019-06-26	2022-08-31	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗体結合ｃｅａ及び４－１ｂｂｌの融合
JP7354306B2 (ja)	2019-06-27	2023-10-02	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021001289A1 (en)	2019-07-02	2021-01-07	F. Hoffmann-La Roche Ag	Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
MX2022001260A (es)	2019-07-31	2022-04-18	Alector Llc	Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
SG11202112491WA (en)	2019-07-31	2021-12-30	Hoffmann La Roche	Antibodies binding to gprc5d
JP2022543551A (ja)	2019-07-31	2022-10-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｇｐｒｃ５ｄに結合する抗体
WO2021050645A1 (en)	2019-09-12	2021-03-18	Genentech, Inc.	Compositions and methods of treating lupus nephritis
US20220372160A1 (en)	2019-09-16	2022-11-24	Surface Oncology, Inc.	Anti-CD39 Antibody Compositions and Methods
PE20221906A1 (es)	2019-09-18	2022-12-23	Genentech Inc	Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
CN114423454A (zh)	2019-09-20	2022-04-29	豪夫迈·罗氏有限公司	抗类胰蛋白酶抗体的给药
US12590171B2 (en)	2019-09-27	2026-03-31	Nanjing GenScript Biotech Co., Ltd.	Anti-VHH domain antibodies and use thereof
EP4048693A1 (en)	2019-09-27	2022-08-31	F. Hoffmann-La Roche AG	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN114945386A (zh)	2019-10-18	2022-08-26	基因泰克公司	使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
EP3816185A1 (en)	2019-11-04	2021-05-05	Numab Therapeutics AG	Multispecific antibody directed against pd-l1 and a tumor-associated antigen
AU2020377930A1 (en)	2019-11-05	2022-05-19	Bristol-Myers Squibb Company	Uses of anti-BCMA chimeric antigen receptors
WO2021092079A1 (en)	2019-11-05	2021-05-14	Acceleron Pharma Inc.	Treatments for systemic sclerosis
AU2020381349A1 (en)	2019-11-05	2022-04-28	F. Hoffmann-La Roche Ag	Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
AU2020378330A1 (en)	2019-11-06	2022-05-12	F. Hoffmann-La Roche Ag	Diagnostic and therapeutic methods for treatment of hematologic cancers
EP4058593A4 (en)	2019-11-12	2023-11-15	Foundation Medicine, Inc.	METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
IL293580A (en)	2019-12-09	2022-08-01	Genentech Inc	Formulations of anti-pd-l1 antibody
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
JP2023506465A (ja)	2019-12-13	2023-02-16	アレクトルエルエルシー	抗ＭｅｒＴＫ抗体及びその使用方法
WO2021119505A1 (en)	2019-12-13	2021-06-17	Genentech, Inc.	Anti-ly6g6d antibodies and methods of use
US12545746B2 (en)	2019-12-16	2026-02-10	2Seventy Bio, Inc.	Anti-BCMA car antibodies, conjugates, and methods of use
CR20220256A (es)	2019-12-18	2022-08-31	Hoffmann La Roche	Anticuerpos que se unen a hla-a2/mage-a4
CN114829408B (zh)	2019-12-20	2024-01-26	山东博安生物技术股份有限公司	用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
EP4081294A2 (en)	2019-12-23	2022-11-02	Genentech, Inc.	Apolipoprotein l1-specific antibodies and methods of use
MY202559A (en)	2019-12-27	2024-05-08	Chugai Pharmaceutical Co Ltd	Anti-ctla-4 antibody and use thereof
CN116234829A (zh)	2020-01-03	2023-06-06	马伦戈治疗公司	抗tcr抗体分子及其用途
MX2022008214A (es)	2020-01-09	2022-08-08	Hoffmann La Roche	Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX2022009391A (es)	2020-01-31	2022-09-26	Genentech Inc	Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
WO2021160154A1 (zh)	2020-02-10	2021-08-19	上海诗健生物科技有限公司	Cldn18.2抗体及其用途
US20230096452A1 (en)	2020-02-10	2023-03-30	Shanghai Escugen Biotechnology Co., Ltd.	Claudin 18.2 antibody and use thereof
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
TWI867190B (zh)	2020-03-19	2024-12-21	美商建南德克公司	同功型選擇性抗-TGF-β抗體及其使用方法
IL296528A (en)	2020-03-24	2022-11-01	Genentech Inc	Tie2-binding agents and methods of use
KR20220159426A (ko)	2020-03-26	2022-12-02	제넨테크, 인크.	감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
US20230121511A1 (en)	2020-03-31	2023-04-20	Chugai Seiyaku Kabushiki Kaisha	Method for producing multispecific antigen-binding molecules
EP4126966A4 (en)	2020-03-31	2024-08-07	Seattle Children's Hospital d/b/a Seattle Children's Research Institute	PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES
JP2023519962A (ja)	2020-03-31	2023-05-15	アレクトルエルエルシー	抗ｍｅｒｔｋ抗体及びその使用方法
AR121706A1 (es)	2020-04-01	2022-06-29	Hoffmann La Roche	Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021202235A1 (en)	2020-04-01	2021-10-07	University Of Rochester	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
CN115298215A (zh)	2020-04-02	2022-11-04	西雅图儿童医院以西雅图儿童研究机构名义经营	特异性地结合与原发性免疫缺陷：维斯科特-奥尔德里奇综合征和x连锁无丙种球蛋白血症相关的肽的抗体
EP4127724A1 (en)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
PH12022552436A1 (en)	2020-04-15	2024-01-03	Hoffmann La Roche	Immunoconjugates
CN115916822A (zh)	2020-04-24	2023-04-04	基因泰克公司	使用抗CD79b免疫缀合物的方法
CR20220531A (es)	2020-04-24	2022-11-28	Hoffmann La Roche	Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
MX2021015024A (es)	2020-04-28	2022-01-18	Univ Rockefeller	Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
EP4143345A1 (en)	2020-04-28	2023-03-08	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
EP4146283A1 (en)	2020-05-03	2023-03-15	Levena (Suzhou) Biopharma Co., Ltd.	Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
EP4149964A2 (en)	2020-05-15	2023-03-22	Apogenix AG	Multi-specific immune modulators
EP3915580A1 (en)	2020-05-29	2021-12-01	Numab Therapeutics AG	Multispecific antibody
CN116323665A (zh)	2020-05-29	2023-06-23	23和我公司	抗cd200r1抗体及其使用方法
MX2022015206A (es)	2020-06-08	2023-01-05	Hoffmann La Roche	Anticuerpos anti-hbv y metodos de uso.
IL298878A (en)	2020-06-11	2023-02-01	Genentech Inc	Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
MX2022015877A (es)	2020-06-16	2023-01-24	Genentech Inc	Metodos y composiciones para tratar cancer de mama triple negativo.
CN115916348A (zh)	2020-06-18	2023-04-04	基因泰克公司	使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
CA3177239A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Protease-activated t cell bispecific antibodies
JP2023530961A (ja)	2020-06-19	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｄ３に結合する抗体
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
KR20230025673A (ko)	2020-06-19	2023-02-22	에프. 호프만-라 로슈 아게	CD3 및 FolR1에 결합하는 항체
BR112022025856A2 (pt)	2020-06-19	2023-01-10	Hoffmann La Roche	Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
JP2023531222A (ja)	2020-06-22	2023-07-21	アルミラル・ソシエダッド・アノニマ	抗ｉｌ－３６抗体およびその使用方法
CN115702168A (zh)	2020-06-23	2023-02-14	豪夫迈·罗氏有限公司	靶向Her2的激动性CD28抗原结合分子
US20220041672A1 (en)	2020-06-24	2022-02-10	Genentech, Inc.	Apoptosis resistant cell lines
CN115916830A (zh)	2020-06-25	2023-04-04	豪夫迈·罗氏有限公司	抗cd3/抗cd28双特异性抗原结合分子
WO2022002112A1 (en)	2020-07-01	2022-01-06	Shandong Boan Biotechnology Co., Ltd.	Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
CA3188000A1 (en)	2020-07-13	2022-01-20	Genentech, Inc.	Cell-based methods for predicting polypeptide immunogenicity
EP4182348A1 (en)	2020-07-17	2023-05-24	Genentech, Inc.	Anti-notch2 antibodies and methods of use
PE20231104A1 (es)	2020-07-21	2023-07-19	Genentech Inc	Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
CN115836122A (zh)	2020-08-07	2023-03-21	基因泰克公司	用于预测多肽免疫原性的基于t细胞的方法
EP4196612A1 (en)	2020-08-12	2023-06-21	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
TW202227616A (zh)	2020-08-21	2022-07-16	美商英麥提克斯股份有限公司	分離ｃｄ８＋選擇ｔ細胞的方法
TW202227625A (zh)	2020-08-28	2022-07-16	美商建南德克公司	宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
EP4204806A1 (en)	2020-08-31	2023-07-05	Genentech, Inc.	Methods for producing antibodies
US11970539B2 (en)	2020-09-14	2024-04-30	Ichnos Sciences SA	Antibodies that bind to IL1RAP and uses thereof
CN116322691A (zh)	2020-09-24	2023-06-23	豪夫迈·罗氏有限公司	T细胞双特异性抗体相关不良反应的预防或减轻
KR20230082632A (ko)	2020-10-05	2023-06-08	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
IL300024A (en)	2020-10-20	2023-03-01	Hoffmann La Roche	Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
AR123855A1 (es)	2020-10-20	2023-01-18	Genentech Inc	Anticuerpos anti-mertk conjugados con peg y métodos de uso
EP3988568A1 (en)	2020-10-21	2022-04-27	Numab Therapeutics AG	Combination treatment
US20230391863A1 (en)	2020-10-23	2023-12-07	Hq Han	Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CN116635419A (zh)	2020-10-30	2023-08-22	豪夫迈·罗氏有限公司	使用CEA CD3双特异性抗体和TGFβ信号传导抑制剂的癌症治疗
CA3196539A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW202227481A (zh)	2020-11-04	2022-07-16	美國洛克菲勒大學	中和抗sars-cov-2抗體
AU2021374594B2 (en)	2020-11-04	2026-03-05	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4241278A2 (en)	2020-11-04	2023-09-13	Celgene Corporation	Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CA3197423A1 (en)	2020-11-04	2022-05-12	Daniel Getts	Engineered chimeric fusion protein compositions and methods of use thereof
KR20230100732A (ko)	2020-11-04	2023-07-05	제넨테크, 인크.	항-cd20/항-cd3 이중특이성 항체의 피하 투여
WO2022101120A1 (en)	2020-11-10	2022-05-19	F. Hoffmann-La Roche Ag	Prevention or mitigation of t-cell engaging agent-related adverse effects
JP2023549316A (ja)	2020-11-16	2023-11-24	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
PE20231556A1 (es)	2020-11-16	2023-10-03	Hoffmann La Roche	Glucoformas de fab ricas en manosa
WO2022120352A1 (en)	2020-12-02	2022-06-09	Alector Llc	Methods of use of anti-sortilin antibodies
WO2022116877A1 (en)	2020-12-02	2022-06-09	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
JP2023552773A (ja)	2020-12-04	2023-12-19	セルジーンコーポレーション	炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
AU2021393752A1 (en)	2020-12-04	2023-05-18	F. Hoffmann-La Roche Ag	Ph-dependent mutant interleukin-2 polypeptides
JP7326584B2 (ja)	2020-12-17	2023-08-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｈｌａ－ｇ抗体及びその使用
WO2022148732A1 (en)	2021-01-06	2022-07-14	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
JP2024505636A (ja)	2021-01-15	2024-02-07	ザロックフェラーユニバーシティー	抗ｓａｒｓ－ｃｏｖ－２中和抗体
EP4281484B1 (en)	2021-01-22	2026-03-18	Hangzhou Baikai Biopharmaceutical Co., Ltd	Anti-her-2/trop-2 constructs and uses thereof
WO2022162587A1 (en)	2021-01-27	2022-08-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
MX2023009022A (es)	2021-02-02	2023-10-23	Numab Therapeutics AG	Anticuerpos multiespecificos con especificidad para ror1 y cd3.
US20240181073A1 (en)	2021-03-03	2024-06-06	Sorrento Therapeutics, Inc.	Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
JP2024512377A (ja)	2021-03-12	2024-03-19	ジェネンテック，インコーポレイテッド	抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
EP4308157A1 (en)	2021-03-15	2024-01-24	Genentech, Inc.	Compositions and methods of treating lupus nephritis
EP4308133A4 (en)	2021-03-17	2025-01-22	Myeloid Therapeutics, Inc.	MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
JP2024512002A (ja)	2021-03-18	2024-03-18	アレクトルエルエルシー	抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
JP2024511610A (ja)	2021-03-23	2024-03-14	アレクトルエルエルシー	コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
EP4314032A1 (en)	2021-03-30	2024-02-07	F. Hoffmann-La Roche AG	Protease-activated polypeptides
KR20230167097A (ko)	2021-04-09	2023-12-07	제넨테크, 인크.	Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
KR20230171994A (ko)	2021-04-16	2023-12-21	셀진 코포레이션	선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
CA3215965A1 (en)	2021-04-19	2022-10-27	Amy Shen	Modified mammalian cells
WO2022223651A1 (en)	2021-04-23	2022-10-27	F. Hoffmann-La Roche Ag	Prevention or mitigation of nk cell engaging agent-related adverse effects
MX2023012699A (es)	2021-04-30	2023-11-21	Hoffmann La Roche	Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022235867A2 (en)	2021-05-06	2022-11-10	The Rockefeller University	Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
AU2022272235A1 (en)	2021-05-11	2023-12-21	Create Medicines, Inc.	Methods and compositions for genomic integration
KR20240007184A (ko)	2021-05-12	2024-01-16	제넨테크, 인크.	미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
AU2022273303A1 (en)	2021-05-14	2023-11-02	Genentech, Inc.	Agonists of trem2
WO2022243261A1 (en)	2021-05-19	2022-11-24	F. Hoffmann-La Roche Ag	Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en)	2021-05-21	2022-11-24	Genentech, Inc.	Modified cells for the production of a recombinant product of interest
AR126009A1 (es)	2021-06-02	2023-08-30	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
US20240270853A1 (en)	2021-06-04	2024-08-15	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2 antibodies and uses thereof
AU2022289684A1 (en)	2021-06-09	2023-10-05	F. Hoffmann-La Roche Ag	Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
US20240279341A1 (en)	2021-06-16	2024-08-22	Alector Llc	Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja)	2021-06-16	2024-07-25	アレクトルエルエルシー	一価の抗ＭｅｒＴＫ抗体及びその使用方法
WO2022263638A1 (en)	2021-06-17	2022-12-22	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
TWI864408B (zh)	2021-06-25	2024-12-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
AU2022299846B2 (en)	2021-06-25	2024-08-15	Chugai Seiyaku Kabushiki Kaisha	Anti–ctla-4 antibody
EP4363449A2 (en)	2021-07-02	2024-05-08	Genentech, Inc.	Methods and compositions for treating cancer
CA3224853A1 (en)	2021-07-14	2023-01-19	Gautham GAMPA	Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
JP2024526880A (ja)	2021-07-22	2024-07-19	ジェネンテック，インコーポレイテッド	脳標的化組成物及びその使用方法
AU2022317820A1 (en)	2021-07-28	2023-12-14	F. Hoffmann-La Roche Ag	Methods and compositions for treating cancer
EP4380980A1 (en)	2021-08-03	2024-06-12	F. Hoffmann-La Roche AG	Bispecific antibodies and methods of use
EP4384553A1 (en)	2021-08-13	2024-06-19	Genentech, Inc.	Dosing for anti-tryptase antibodies
EP4388014A1 (en)	2021-08-19	2024-06-26	F. Hoffmann-La Roche AG	Multivalent anti-variant fc-region antibodies and methods of use
IL310382A (en)	2021-08-27	2024-03-01	Genentech Inc	Methods for treating tau pathologies
WO2023034750A1 (en)	2021-08-30	2023-03-09	Genentech, Inc.	Anti-polyubiquitin multispecific antibodies
CN118541392A (zh)	2021-09-28	2024-08-23	准星生物医药有限公司	多种形式的分子复合物
JPWO2023053282A1 (2)	2021-09-29	2023-04-06
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202333781A (zh)	2021-10-08	2023-09-01	日商中外製藥股份有限公司	抗ｈｌａ－ｄｑ２﹒５抗體製劑
WO2023062048A1 (en)	2021-10-14	2023-04-20	F. Hoffmann-La Roche Ag	Alternative pd1-il7v immunoconjugates for the treatment of cancer
AU2022362681A1 (en)	2021-10-14	2024-04-04	F. Hoffmann-La Roche Ag	New interleukin-7 immunoconjugates
EP4419558A1 (en)	2021-10-19	2024-08-28	Alector LLC	Anti-cd300lb antibodies and methods of use thereof
TW202325742A (zh)	2021-11-01	2023-07-01	瑞士商赫孚孟拉羅股份公司	使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
JP2024543404A (ja)	2021-11-10	2024-11-21	エフ．ホフマン－ラロシュアーゲー	親水性アザジベンゾシクロオクチン誘導体およびこれらの親水性アザジベンゾシクロオクチン誘導体との無金属クリック反応
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP4180518A1 (en)	2021-11-12	2023-05-17	Istituto Europeo di Oncologia S.r.l.	T cells and uses thereof
KR20240102971A (ko)	2021-11-16	2024-07-03	제넨테크, 인크.	모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
WO2023088876A1 (en)	2021-11-16	2023-05-25	Apogenix Ag	Multi-specific immune modulators
WO2023088889A1 (en)	2021-11-16	2023-05-25	Apogenix Ag	CD137 ligands
EP4183800A1 (en)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Novel sars-cov-2 neutralizing antibodies
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
JP2024546589A (ja)	2021-12-14	2024-12-26	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｌａ－ａ２／ｍａｇｅ－ａ４×ｃｄ３二重特異性抗体及び４－１ｂｂ（ｃｄ１３７）アゴニストを使用したがんの治療
CA3241407A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
JP2025501522A (ja)	2021-12-17	2025-01-22	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｏｘ４０抗体及び使用方法
WO2023114544A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
CN118488965A (zh)	2021-12-17	2024-08-13	上海复宏汉霖生物技术股份有限公司	抗ox40抗体、多特异性抗体及其使用方法
CR20240246A (es)	2021-12-20	2024-07-19	Hoffmann La Roche	Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20230322958A1 (en)	2022-01-19	2023-10-12	Genentech, Inc.	Anti-Notch2 Antibodies and Conjugates and Methods of Use
AR128331A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
EP4469159A1 (en)	2022-01-27	2024-12-04	The Rockefeller University	Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
EP4223302A1 (en)	2022-02-08	2023-08-09	Universität Heidelberg	Oncolytic measles virus encoding a bike and methods of use thereof in treating cancer
EP4489790A1 (en)	2022-03-10	2025-01-15	Vivasor, Inc.	Antibody-drug conjugates and uses thereof
WO2024026472A2 (en)	2022-07-29	2024-02-01	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
WO2023180353A1 (en)	2022-03-23	2023-09-28	F. Hoffmann-La Roche Ag	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202402790A (zh)	2022-03-25	2024-01-16	英商梅迪繆思有限公司	減少呼吸系統感染之方法
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
JP2025511000A (ja)	2022-03-28	2025-04-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	インターフェロンガンマバリアントおよびこれを含む抗原結合分子
IL315770A (en)	2022-04-01	2024-11-01	Genentech Inc	Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
TWI882313B (zh)	2022-04-13	2025-05-01	美商建南德克公司	治療性蛋白質之醫藥組成物及使用方法
CN119013300A (zh)	2022-04-13	2024-11-22	豪夫迈·罗氏有限公司	抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
US20250346653A1 (en)	2022-04-29	2025-11-13	Broadwing Bio Inc.	Bispecific antibodies and method of treating ocular disease
WO2023212293A1 (en)	2022-04-29	2023-11-02	Broadwing Bio Llc	Complement factor h related 4-specific antibodies and uses thereof
US20250296996A1 (en)	2022-04-29	2025-09-25	Broadwing Bio, Inc.	Angiopoietin-related protein 7-specific antibodies and uses thereof
CA3257258A1 (en)	2022-05-03	2023-11-09	Genentech, Inc.	Anti-Ly6E antibodies, immunoconjugates, and their uses
CN119317641A (zh)	2022-05-11	2025-01-14	基因泰克公司	针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
US20250295771A1 (en)	2022-05-11	2025-09-25	Celgene Corporation	Methods and uses related to t cell therapy and production of same
WO2023218431A1 (en)	2022-05-13	2023-11-16	BioNTech SE	Rna compositions targeting hiv
WO2023230548A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Method for predicting response to a t cell therapy
US20230416412A1 (en)	2022-05-31	2023-12-28	Hoffmann-La Roche Inc.	Prevention or mitigation of t-cell engaging agent-related adverse effects
EP4537107A2 (en)	2022-06-07	2025-04-16	Genentech, Inc.	Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
JP2025523020A (ja)	2022-07-13	2025-07-17	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
CA3261510A1 (en)	2022-07-19	2024-01-25	F. Hoffmann-La Roche Ag	DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
AR129991A1 (es)	2022-07-22	2024-10-23	Bristol Myers Squibb Co	Anticuerpos que se unen a la pad4 humana y usos de los mismos
CA3261989A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES
WO2024026471A1 (en)	2022-07-29	2024-02-01	Alector Llc	Cd98hc antigen-binding domains and uses therefor
TW202415679A (zh)	2022-07-29	2024-04-16	美商阿列克特有限責任公司	抗ｇｐｎｍｂ抗體及其使用方法
WO2024038095A1 (en)	2022-08-16	2024-02-22	Iome Bio	NOVEL ANTI-RGMb ANTIBODIES
JP2025531738A (ja)	2022-09-01	2025-09-25	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法及び診断方法
AU2023342647A1 (en)	2022-09-15	2025-02-20	Avidicure Ip B.V.	Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
JP2025534285A (ja)	2022-09-29	2025-10-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	プロテアーゼ活性化ポリペプチド
WO2024068996A1 (en)	2022-09-30	2024-04-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
TW202421664A (zh)	2022-10-07	2024-06-01	美商建南德克公司	用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
TW202423970A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh)	2022-10-10	2024-08-01	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024086796A1 (en)	2022-10-20	2024-04-25	Alector Llc	Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024091991A1 (en)	2022-10-25	2024-05-02	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
WO2024094741A1 (en)	2022-11-03	2024-05-10	F. Hoffmann-La Roche Ag	Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
CN120265651A (zh)	2022-11-25	2025-07-04	中外制药株式会社	用于生产蛋白质的方法
TW202440623A (zh)	2022-11-28	2024-10-16	美商艾洛基因醫療公司	靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115349A1 (en)	2022-11-29	2024-06-06	F. Hoffmann-La Roche Ag	Improved cancer immunotherapy
WO2024120516A1 (zh)	2022-12-08	2024-06-13	南京诺唯赞生物科技股份有限公司	特异性结合rsv的抗体
CN120693406A (zh)	2022-12-12	2025-09-23	基因泰克公司	优化多肽唾液酸含量
JP2026501282A (ja)	2022-12-20	2026-01-14	ジェネンテック，インコーポレイテッド	Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いて膵臓がんを処置する方法
WO2024141955A1 (en)	2022-12-28	2024-07-04	BioNTech SE	Rna compositions targeting hiv
EP4646270A2 (en)	2023-01-06	2025-11-12	Alector LLC	Anti-il18 binding protein antibodies and methods of use thereof
WO2024149821A1 (en)	2023-01-13	2024-07-18	F. Hoffmann-La Roche Ag	Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
WO2024155807A1 (en)	2023-01-18	2024-07-25	Genentech, Inc.	Multispecific antibodies and uses thereof
KR20250129814A (ko)	2023-01-18	2025-08-29	타이리간드 바이오사이언스 (상하이) 리미티드	항체-약물 접합체 및 이의 용도
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
TW202436339A (zh)	2023-01-31	2024-09-16	瑞士商赫孚孟拉羅股份公司	治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024163009A1 (en)	2023-01-31	2024-08-08	Genentech, Inc.	Methods and compositions for treating urothelial bladder cancer
JP2026509243A (ja)	2023-03-10	2026-03-17	ジェネンテック，インコーポレイテッド	プロテアーゼとの融合およびその使用
EP4680638A1 (en)	2023-03-13	2026-01-21	F. Hoffmann-La Roche AG	Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4-1bb (cd137) agonist
JP2026510584A (ja)	2023-03-13	2026-04-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｐｄ１－ｌａｇ３二重特異性抗体およびｈｌａ－ｇｔ細胞二重特異性抗体を用いる併用療法
TW202446789A (zh)	2023-03-31	2024-12-01	美商建南德克公司	抗αｖβ８整合素抗體及使用方法
EP4687996A1 (en)	2023-04-05	2026-02-11	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
EP4687995A1 (en)	2023-04-05	2026-02-11	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
EP4687997A2 (en)	2023-04-05	2026-02-11	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
EP4694940A1 (en)	2023-04-12	2026-02-18	Astrazeneca AB	Steap2-targeted compounds and use thereof
EP4698230A2 (en)	2023-04-17	2026-02-25	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024223769A1 (en)	2023-04-26	2024-10-31	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	H3 histone mutein binding compounds
WO2024226794A1 (en)	2023-04-26	2024-10-31	The Trustees Of Indiana University	Composition and methods for treatment of spinal cord injury and traumatic brain injury
EP4703374A1 (en)	2023-04-28	2026-03-04	Shenzhen Shenxin Biotechnology Co., Ltd.	Modified delivery vector and use thereof
WO2024227154A1 (en)	2023-04-28	2024-10-31	Broadwing Bio Llc	Complement component 3 (c3)-specific antibodies and uses thereof
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR132623A1 (es)	2023-05-08	2025-07-16	Hoffmann La Roche	PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
IL324490A (en)	2023-05-10	2026-01-01	Genentech Inc	Methods and preparations for treating cancer
CN121263435A (zh)	2023-05-16	2026-01-02	豪夫迈·罗氏有限公司	Pd-1调节的il-2免疫细胞因子及其用途
IL324547A (en)	2023-05-18	2026-01-01	Clade Therapeutics Inc	Inhibition of natural killer cell cytotoxicity against cellular therapies
TW202448933A (zh)	2023-05-31	2024-12-16	美商建南德克公司	用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
EP4720120A1 (en)	2023-06-01	2026-04-08	F. Hoffmann-La Roche AG	Bispecific antibodies targeting bcma and cd28
EP4720121A1 (en)	2023-06-01	2026-04-08	F. Hoffmann-La Roche AG	Immunostimulatory antigen binding molecules that specifically bind to bcma
KR20260026086A (ko)	2023-06-21	2026-02-25	에프. 호프만-라 로슈 아게	Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법
TW202502809A (zh)	2023-06-22	2025-01-16	美商建南德克公司	抗體及其用途
EP4731255A1 (en)	2023-06-22	2026-04-29	Genentech, Inc.	Treatment of multiple myeloma
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2025024265A1 (en)	2023-07-21	2025-01-30	Bristol-Myers Squibb Company	Methods of assessing citrullination and activity of pad4 modulators
CN121712799A (zh)	2023-07-26	2026-03-20	豪夫迈·罗氏有限公司	与cd3结合的抗体
WO2025027579A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Rna compositions targeting hiv
CN121866336A (zh)	2023-08-03	2026-04-14	百欧恩泰欧洲股份公司	靶向hiv的rna组合物
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
AU2024323186A1 (en)	2023-08-09	2026-01-15	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025042786A1 (en)	2023-08-18	2025-02-27	Flagship Pioneering Innovations Vi, Llc	Compositions comprising circular polyribonucleotides and uses thereof
WO2025049277A1 (en)	2023-08-25	2025-03-06	Genentech, Inc.	Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
AU2024343373A1 (en)	2023-09-14	2026-02-12	F. Hoffmann-La Roche Ag	Antibody formulation
AR133909A1 (es)	2023-09-25	2025-11-12	Hoffmann La Roche	ANTICUERPO QUE SE UNE A C3bBb
US12122842B1 (en)	2023-09-27	2024-10-22	R&D Systems, Inc.	Human CD30-specific binding proteins and uses thereof
WO2025085489A1 (en)	2023-10-17	2025-04-24	Bristol-Myers Squibb Company	Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025099120A1 (en)	2023-11-09	2025-05-15	F. Hoffmann-La Roche Ag	Multispecific antibodies with conditional activity
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106634A1 (en)	2023-11-17	2025-05-22	Genentech, Inc.	Mcl-1 inhibitor compounds and use in antibody drug conjugates
WO2025117848A1 (en)	2023-12-01	2025-06-05	Genentech, Inc.	Low-viscosity variants of antibodies
WO2025125386A1 (en)	2023-12-14	2025-06-19	F. Hoffmann-La Roche Ag	Antibodies that bind to folr1 and methods of use
WO2025129010A1 (en)	2023-12-14	2025-06-19	Genentech, Inc.	Methods of structure determination using antibodies
WO2025132503A1 (en)	2023-12-20	2025-06-26	F. Hoffmann-La Roche Ag	Antibodies binding to ceacam5
WO2025137086A1 (en)	2023-12-20	2025-06-26	Genentech, Inc.	Reducing alpha-gal
WO2025133042A2 (en)	2023-12-22	2025-06-26	F. Hoffmann-La Roche Ag	Activatable fusion proteins and methods of use
WO2025149633A1 (en)	2024-01-12	2025-07-17	Laigo Bio B.V.	Bispecific antigen binding proteins
TW202539700A (zh)	2024-01-16	2025-10-16	美商建南德克公司	用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
WO2025155602A1 (en)	2024-01-16	2025-07-24	Genentech, Inc.	Method of treating hemophilia a
WO2025166040A1 (en)	2024-01-31	2025-08-07	Alector Llc	Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en)	2024-01-31	2025-08-07	Alector Llc	Compositions comprising progranulin and uses thereof
WO2025166045A1 (en)	2024-01-31	2025-08-07	Alector Llc	β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166042A1 (en)	2024-01-31	2025-08-07	Alector Llc	Cd98hc antigen-binding domains and uses therefor
WO2025174974A1 (en)	2024-02-14	2025-08-21	Bristol-Myers Squibb Company	Anti-cd33 antibodies and uses thereof
WO2025181189A1 (en)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025191136A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025202147A1 (en)	2024-03-27	2025-10-02	F. Hoffmann-La Roche Ag	Interleukin-7 immunoconjugates
WO2025215060A1 (en)	2024-04-11	2025-10-16	F. Hoffmann-La Roche Ag	Antibodies that specifically bind modified oligonucleotides
WO2025226808A1 (en)	2024-04-24	2025-10-30	Genentech, Inc.	Compositions and methods of treating lupus nephritis
WO2025250969A1 (en)	2024-05-31	2025-12-04	Vertex Pharmaceuticals Incorporated	Anti-cd74 antibodies, conjugates and uses thereof
WO2025255349A1 (en)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025255405A1 (en)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Anti-fap antibodies and uses thereof
US20260056209A1 (en)	2024-06-14	2026-02-26	Gilead Sciences, Inc.	Anti-ccr8 antibodies and uses thereof
WO2025264572A1 (en)	2024-06-17	2025-12-26	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
US20260001942A1 (en)	2024-06-21	2026-01-01	H. Lundbeck A/S	Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026003224A2 (en)	2024-06-26	2026-01-02	Iomx Therapeutics Ag	Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026041568A1 (en)	2024-08-20	2026-02-26	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and dotam
WO2026052650A1 (en)	2024-09-05	2026-03-12	F. Hoffmann-La Roche Ag	Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
WO2026072685A1 (en)	2024-09-25	2026-04-02	Genentech, Inc.	Compositions and methods of treating lupus nephritis
WO2026073840A1 (en)	2024-10-01	2026-04-09	F. Hoffmann-La Roche Ag	Antibodies that bind to cd3 and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en) *	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4556676A (en) *	1979-11-01	1985-12-03	Pfizer Inc.	Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

1991
- 1991-07-11 GB GB919114948A patent/GB9114948D0/en active Pending
1992
- 1992-07-03 EP EP92914659A patent/EP0595851B1/en not_active Expired - Lifetime
- 1992-07-03 JP JP5501952A patent/JP2563754B2/ja not_active Expired - Fee Related
- 1992-07-03 US US08/178,240 patent/US5442116A/en not_active Expired - Fee Related
- 1992-07-03 DK DK92914659.5T patent/DK0595851T3/da active
- 1992-07-03 ES ES92914659T patent/ES2082481T3/es not_active Expired - Lifetime
- 1992-07-03 CA CA002109818A patent/CA2109818C/en not_active Expired - Fee Related
- 1992-07-03 WO PCT/EP1992/001496 patent/WO1993001161A1/en not_active Ceased
- 1992-07-03 DE DE69207601T patent/DE69207601T2/de not_active Expired - Fee Related
- 1992-07-03 AT AT92914659T patent/ATE132848T1/de not_active IP Right Cessation
- 1992-07-09 PT PT100673A patent/PT100673B/pt not_active IP Right Cessation
- 1992-07-10 IE IE922249A patent/IE71029B1/en not_active IP Right Cessation
1994
- 1994-01-10 FI FI940105A patent/FI112209B/fi not_active IP Right Cessation
1996
- 1996-02-28 GR GR960400546T patent/GR3019122T3/el unknown

Also Published As

Publication number	Publication date
CA2109818C (en)	2003-01-21
GB9114948D0 (en)	1991-08-28
FI940105A0 (fi)	1994-01-10
DK0595851T3 (da)	1996-02-12
EP0595851B1 (en)	1996-01-10
WO1993001161A1 (en)	1993-01-21
PT100673A (pt)	1993-09-30
JPH06509079A (ja)	1994-10-13
EP0595851A1 (en)	1994-05-11
DE69207601D1 (de)	1996-02-22
PT100673B (pt)	1999-07-30
GR3019122T3 (2)	1996-05-31
IE71029B1 (en)	1997-01-15
FI112209B (fi)	2003-11-14
ES2082481T3 (es)	1996-03-16
CA2109818A1 (en)	1993-01-12
US5442116A (en)	1995-08-15
FI940105L (fi)	1994-01-10
IE922249A1 (en)	1993-01-13
JP2563754B2 (ja)	1996-12-18
DE69207601T2 (de)	1996-05-23

Legal Events

Date	Code	Title	Description
1996-07-15	UEP	Publication of translation of european patent specification
2008-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE132848T1 (de)	1996-01-15	Verfahren zur herstellung von sertralin- zwischenprodukten
ATE127779T1 (de)	1995-09-15	Verfahren zur herstellung von sertralin.
ATE109456T1 (de)	1994-08-15	Verfahren zur stereoselektiven herstellung von phenylisoserinderivaten.
DE59108707D1 (de)	1997-06-26	Verfahren zur Herstellung von Oxetanonen
HU9501585D0 (en)	1995-08-28	Azoxycyanobenzene-derivatives, process for their preparation, fungicidal compositions containing them
DE69627166D1 (de)	2003-05-08	Verfahren zur herstellung von 2-chlor-5-chlomethyl-thiazol-derivaten
BR9507168A (pt)	1997-09-02	Composto e processo para a preparação do mesmo
DE59010545D1 (de)	1996-11-28	Phosphinesterhaltige N-Acyl-2-aminosäureamide, Verfahren zu ihrer Herstellung und N-Acyl-2-aminosäurenitrile als Vorprodukte
PT100682A (pt)	1993-08-31	Agentes anti-helminticos derivados de benzimidazole e processo para a sua preparacao
GB9313145D0 (en)	1993-08-11	Process
DE69326767D1 (de)	1999-11-18	Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
HU886767D0 (en)	1990-09-28	Process for the preparation of new 20,21-dinor-eburnamenine derivatives, new intermediates thereof, as well as pharmaceutical compositions containing said compounds as active ingredients
DE69406451D1 (de)	1997-11-27	Verfahren zur herstellung von n-carbonylarylimine als zwischenprodukte in der synthese von therapeutisch aktiven taxol-derivaten
ATE157655T1 (de)	1997-09-15	Verfahren zur herstellung von gegebenfalls 2- substituierten 5-chlorimidazolen
DE69310369D1 (de)	1997-06-05	Verfahren zur herstellung von 3,3-diarylacrylsäureamiden
ATE147744T1 (de)	1997-02-15	Verfahren zur herstellung von sulfonylpristinamycin iib
ATE135350T1 (de)	1996-03-15	Verfahren zur herstellung von 2-amino-7- nitrobenzothiazolen
DE69620244D1 (de)	2002-05-02	Verfahren zur herstellung von prostaglandin e1